Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors
Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors
复制标题
DOI：
10.1002/(sici)1096-9896(199707)182:3
复制
发表时间：
1997-07-01
影响因子：
7.3
通讯作者：
Culig, Z
中科院分区：
文献类型：
--
作者：
Hobisch, A;Hittmair, A;Culig, Z
雌激素受体(ER)和孕激素受体(PR)已被几位作者报道存在于人类前列腺的间质细胞中。雌激素受体和孕激素受体在前列腺上皮细胞中的表达存在争议。与以前的发现相反，最近的一些出版物表明，这些受体也存在于来自转移性病变的人前列腺癌细胞系中。重新检测这些细胞系中ER和PR的表达，以确定它们在未接受任何内分泌治疗的患者的淋巴转移中的存在，以及从内分泌治疗失败的患者获得的远处转移中的存在。用逆转录聚合酶链式反应、配体结合分析和免疫组织化学方法检测ER和PR在LNCaP、PC-3和DU-145细胞中的表达。在所有技术的应用下，这三个细胞系被发现ER和PR都是阴性的。对4例未接受内分泌治疗的前列腺癌根治术患者的淋巴结转移和17例内分泌治疗失败的患者姑息性手术后的远处转移进行了免疫组织化学分析。免疫组织化学检测21例转移瘤ER、PR均为阴性。这些结果不支持最近发展的概念，即前列腺癌转移中存在孕激素和孕激素受体。(C)1997年John Wiley&Sons，Ltd.
Oestrogen receptors (ER) and progesterone receptors (PR) have been reported by several authors in the stromal cells of the human prostate. Controversial results exist on the expression of ER and PR in epithelial cells of the prostate. Some recent publications, in contrast to previous findings, have suggested that these receptors are also present in human prostate cancer cell lines derived from metastatic lesions. The expression of ER and PR in these cell lines has been re-examined to determine their presence in lymph node metastases from patients who did not receive any kind of endocrine therapy and in distant metastases obtained from patients who failed endocrine treatment. ER and PR expression in LNCaP, PC-3, and DU-145 cells was assessed by means of the reverse transcriptase-polymerase chain reaction, ligand binding assays, and immunohistochemistry. With all the techniques applied, the three cell lines were found to be negative for both ER and PR. Immunohistochemical analyses were performed in four lymph node metastases obtained at radical prostatectomy from patients who did not receive endocrine therapy and in 17 distant metastases obtained at palliative surgery from patients who failed endocrine therapy. All 21 metastases were negative for ER and PR on immunohistochemistry. These results do not support the recently developed concept that receptors for pestrogenic and progestagenic steroids are present in metastases from human prostate cancer. (C) 1997 by John Wiley & Sons, Ltd.